What is the recommended dosing regimen for remdesivir (including loading and maintenance doses) in hospitalized adults and children with COVID‑19?

Remdesivir Dosing for COVID-19

For hospitalized adults with COVID-19, administer remdesivir as a 200 mg intravenous loading dose on day 1, followed by 100 mg daily maintenance doses for a total treatment duration of 5 days in most patients. 1

Adult Dosing Regimen

Standard Course (5 Days)

• Day 1: 200 mg IV loading dose
• Days 2-5: 100 mg IV daily (total of 5 doses)

This 5-day course is appropriate for most hospitalized patients with COVID-19 2, 1. The evidence shows that a 5-day course provides similar clinical benefits to a 10-day course while reducing serious adverse events, particularly in patients not requiring mechanical ventilation or ECMO 2, 3.

Extended Course (10 Days)

Consider extending treatment to 10 days (200 mg on day 1, then 100 mg daily for days 2-10) for patients whose condition worsens during the initial 5-day course to require supplemental oxygen but not mechanical ventilation. However, current evidence is insufficient to definitively support treatment beyond 5 days 2. The decision to extend should be based on clinical judgment, as the 10-day course showed little to no additional mortality benefit compared to the 5-day regimen 2.

Pediatric Dosing

Children ≥12 Years and ≥40 kg

Use the adult dosing regimen:

• Day 1: 200 mg IV
• Days 2-5: 100 mg IV daily 1

Children ≥28 Days to <12 Years

Weight-based dosing:

• Day 1: 5 mg/kg IV loading dose
• Days 2-5: 2.5 mg/kg IV daily

Specific weight categories:

• ≥40 kg: Use adult dosing (200 mg, then 100 mg daily)
• 20 to <40 kg: 5 mg/kg loading, then 2.5 mg/kg daily
• 12 to <20 kg: 5 mg/kg loading, then 2.5 mg/kg daily
• 3 to <12 kg: 5 mg/kg loading, then 2.5 mg/kg daily 1

Neonates and Infants <28 Days

• ≥1.5 kg: Weight-based dosing as above, with careful monitoring 1

Administration Details

• Route: Intravenous infusion only
• Infusion time: 30-120 minutes 1
• Setting: Hospital or acute care facility capable of providing similar level of care 2

Clinical Decision Algorithm

Initiate remdesivir if:

1. Patient is hospitalized primarily for COVID-19 (not incidental positive test)
2. Patient has evidence of lower respiratory tract involvement
3. Patient requires supplemental oxygen but not mechanical ventilation (strongest evidence) 2, 4

Consider remdesivir for:

• Critically ill patients on mechanical ventilation or ECMO (weaker evidence, but may be beneficial) 5, 6

Do NOT routinely use for:

• Patients hospitalized for unrelated conditions who incidentally test positive for SARS-CoV-2 2

Important Caveats

Renal Function

• No dose adjustment required regardless of renal function, including patients with eGFR <30 mL/min/1.73 m² 1
• FDA previously recommended against use in severe renal impairment, but this restriction has been removed based on safety data 7
• Monitor kidney function at baseline and during treatment 2

Hepatic Function

• Monitor liver enzymes at baseline and during treatment 2
• Elevated ALT (11%) and AST (10%) are the most common adverse events in pediatric patients 8
• Use with caution in moderate to severe hepatic impairment, as exposures may be increased 1

Timing Considerations

The benefit of remdesivir appears greatest when initiated early in the disease course, particularly in patients requiring low-flow oxygen support 4. Evidence for benefit in patients already on mechanical ventilation is less robust 2.

Pregnancy

Remdesivir exposures during pregnancy are similar to non-pregnant individuals, supporting use of standard adult dosing 1.